****Published February 2022****

MarketVIEW: RSV vaccines and monoclonals (CAT: VAMV023)

Product Name	:	**MarketVIEW:** RSV vaccines and monoclonals
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (~385 slides .pdf) + forecast model (.xls)
Therapeutic Area	:	**RSV vaccines and monoclonals**
Publication date	:	February 2022
Catalogue No	:	VAMV023

Background

Human respiratory syncytial virus (RSV) is one of the most common viruses to infect children worldwide and now is recognized as an important pathogen in adults, especially the elderly. Globally, each year, there are over 33m episodes of RSV-associated acute lower respiratory infection (RSV-ARI) in children <5 yrs resulting in at least 3.2m hospital admissions and 59,600 in-hospital deaths *(Shi T et al., 2017).* In children <5 yrs, the burden of RSV exceeds that of influenza and other respiratory viral pathogens. In adults, about 1.5m episodes of RSV-ARI occur in industrialized countries. Globally, 336,000 hospital admissions and 14,000 in-hospital deaths have been estimated although the true burden is believed to be higher *(Shi T et al., 2020).*

Several pivotal **Phase III studies** are ongoing with readouts expected in 2022. Major companies such as **Pfizer**, **GSK Biologicals**, **Janssen NV**, **ModernaTX**, **Sanofi Pasteur** and **Bavarian Nordic** have a range of vaccine approaches targeting the maternal, infant/toddler and older adult/elderly segments. Newer long-acting monoclonal antibodies such as **nirsevimab**, MEDI8897 (Sanofi/AstraZeneca) have recently met Phase III trial endpoints (MELODY/MEDLEY) and will soon undergo global regulatory submissions. Merck & Co's **clesrovimab** (MK-1654) has also recently entered Phase II/III clinical studies.

This **MarketVIEW** product is a comprehensive Executive Presentation and interactive MS-Excel forecast model which investigate the scenario-based interplay and commercial potential of 4 RSV vaccine profiles along with monoclonal antibodies in all relevant target groups (e.g., maternal, infant/toddler, at-risk, older adult and elderly) to **2037**. **52 countries** and sub-regions are included (public/private sector) where the impact of different country specific pricing analogues and cohort target ranges can be explored. Country specific roll-out is forecasted according to specific local factors and RSV transmission patterns. Issues regarding the positioning of monoclonals in the at-birth segment versus maternal vaccination are explored. The report contains a thorough review of disease background/epidemiology/cost-effectiveness along with **vaccinology/R&D competitive landscape** with an emphasis on future product differentiators. This product is ideally suited to organisations wishing to access an up-to-date advanced global quantification of the RSV vaccine/monoclonal opportunity.

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to RSV vaccines and monoclonals in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised including SARS-CoV-2 and seasonal influenza vaccines.

PRODUCT CONTENTS:

Published February 2022 (CAT No: VAMV023)
****This product is a summary presentation (.pdf), an MS-workbook (.xls)

Contents – Summary presentation (.pdf)

SNAPSHOT

PAGES: >385 slides fully referenced/sourced. Available in .pdf form

Contents – MS-Excel workbook (.xls)

United States [5 target product profiles, public and private sector]
Canada
UK
France
Germany
Italy
Spain
Other Europe 1 & 2
Brazil
India
China
Russia
Mexico
Australia, Japan, South Korea
PAHO (other)
International (other)

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

PRODUCT COST:
VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **$contact us**/ GBP **£contact us#** (Global license only)*

*Global = North America, Europe or ROW (non-exclusive, non-transferable license)
For orders in the UK, VAT at 20% will be added to final invoice total
 # - indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:
To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.

BIBLIOGRAPHY

- 400 References – available upon request

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired while providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

Since 2007

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 927049 **e-mail: info@vaczine-analytics.com**